New Vaccine Platform for COVID-19 Using Mutated Virus
Author Information
Author(s): Zhang En, Ke Yong, Ran Weihong, Zhang Yu, Li Ruihang, Fang Xinkui, Wang Lei, Zhang Baohong, Sun Tao
Primary Institution: Shanghai Jiao Tong University
Hypothesis
Can a single-cycle M-protein mutated vesicular stomatitis virus (VSVMT) serve as a safe and effective mucosal vaccine platform for delivering SARS-CoV-2 immunogens?
Conclusion
The study found that the VSVMT-S2P vaccine candidate is safe and can effectively stimulate immune responses in both healthy and immunocompromised animals.
Supporting Evidence
- The VSVMT-S2P vaccine candidate is safe in healthy and immunocompromised animals.
- Single-cycle VSVMT can stimulate effective immune responses with just one dose.
- Intranasal administration of VSVMT-S2P did not lead to significant toxicity in hamsters.
- The vaccine induced significant neutralizing antibody responses in serum.
- Immunocompromised animals showed lower immune responses compared to healthy ones.
Takeaway
Researchers created a new vaccine using a modified virus that is safe and can help the body fight COVID-19 with just one shot.
Methodology
The study involved administering the VSVMT-S2P vaccine to healthy and immunocompromised hamsters and mice via intranasal and intramuscular routes, followed by monitoring immune responses and safety indicators.
Limitations
The immune responses in immunocompromised animals were lower and delayed compared to healthy animals.
Participant Demographics
Healthy and immunocompromised hamsters and BALB/c mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website